Q1 2025 Personalis Inc Earnings Call Transcript

May 6, 2025 / 09:00 PM GMT

Release Date Price: $4 (-6.10%)

Transcript 10-Q8-K

Key Points

Positve

Personalis Inc (PSNL) achieved revenues of over $20 million in Q1 2025, with a significant increase in molecular tests delivered.
The company is well-positioned in the growing MRD market, expected to mature into a $20 billion market.
Personalis Inc (PSNL) reported strong biopharma revenue growth, driven by the adoption of their Next Personal test.
The company has a strong cash position with $185.7 million in cash and equivalents, providing a comfortable runway for growth.
Personalis Inc (PSNL) is making significant progress in clinical usage and reimbursement efforts, with positive feedback from physicians and high retention rates.

Negative

Despite revenue growth, Personalis Inc (PSNL) reported a net loss of $15.8 million for Q1 2025.
The company faces challenges with unreimbursed clinical test costs impacting gross margins.
There is uncertainty around the timing and outcome of reimbursement decisions, which could affect future revenue.
Personalis Inc (PSNL) is experiencing some headwinds in the pharmaceutical market due to government trade issues and project deferrals.
The company is still in the early stages of data maturation and publication for certain cancer indications, which could delay reimbursement submissions.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PSNL.OQ - Personalis Inc
Q1 2025 Personalis Inc Earnings Call
May 06, 2025 / 09:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings. Welcome to the Personalysis first quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press 0 on your telephone keypad. Please note this conference is being recorded.

I would now return the call over to Caroline Corner. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator. Welcome to Personallysis first quarter 2025 earnings call. Joining today's call are

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.